antiplatelet/moždani udar

Veza se sprema u međuspremnik

Odaberite vrstu sortiranja

Page 1 od 6329 rezultati

Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

OBJECTIVE Randomised trials have shown the efficacy of antiplatelet therapy with cilostazol to prevent secondary ischaemic stroke. Recently, cilostazol has been reported to prevent the development and/or recurrence of atrial fibrillation (AF), which can potentially prevent cardioembolic stroke in

Antiplatelet cilostazol is effective in the prevention of pneumonia in ischemic stroke patients in the chronic stage.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

We have previously reported that the phosphodiesterase inhibitor cilostazol, an antiplatelet agent, is effective and safe for secondary prevention of recurrent cerebral infarction (Cilostazol Stroke Prevention Study; CSPS). We now report the efficacy of this drug in the prevention of pneumonia in

Effectiveness and safety of antiplatelet therapy in stroke recurrence prevention in patients with liver cirrhosis: a 2-year follow-up study.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

BACKGROUND Data are limited on antiplatelet therapy for ischemic stroke prevention in liver cirrhosis patients. METHODS This retrospective study identified cases of liver cirrhosis from the National Health Insurance Research Database. Antiplatelet therapy was administered for 2 years to patients who

Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Which of the available antiplatelet therapies should be preferred for secondary prevention of recurrent ischemic stroke has been contentious. OBJECTIVE We applied the Duke Stroke Policy Model (DSPM) to reconsider this issue, paying particular attention to the degree of uncertainty in the estimates

Antiplatelet therapies for secondary stroke prevention: an update on clinical and cost-effectiveness.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Stroke exacts a huge toll physically, mentally and economically. Antiplatelet therapy is the cornerstone of secondary stroke prevention, and proven drugs available to successfully realize this therapeutic strategy for the long term include aspirin, dipyridamole plus aspirin and clopidogrel. However,

Cost-effectiveness of antiplatelet therapy for secondary stroke prevention.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Antiplatelet therapy is recommended over anticoagulants for the secondary prevention of vascular death in patients with noncardioembolic ischemic stroke or transient ischemic attack based upon the 2006 American Heart Association/American Stroke Association guidelines for the prevention of stroke and

Oral antiplatelet therapy for acute ischaemic stroke.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

BACKGROUND In people with acute ischaemic stroke, platelets become activated and can cause blood clots to form and block an artery in the brain, resulting in damage to part of the brain. Such damage gives rise to the symptoms of stroke. Antiplatelet therapy might reduce the volume of brain damaged

Influences of an NR1I2 polymorphism on heterogeneous antiplatelet reactivity responses to clopidogrel and clinical outcomes in acute ischemic stroke patients.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Pregnane X receptor (PXR) is a member of nuclear receptor subfamily 1 (NR1I2) that is a transcriptional regulator of several metabolic enzymes involved in clopidogrel metabolism. In this study we identified and evaluated the contributions of single nucleotide polymorphisms (SNPs) in NR1I2 and

Antiplatelet therapy in secondary ischemic stroke prevention - a short review.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Platelets play an essential role in atherothrombosis and for this reason they are the primary target of antithrombotic therapy in ischemic stroke. We discussed here the evidence for efficacy and safety of current knowledge in antiplatelet therapy for stroke prevention after an acute ischemic stroke

Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Although dual antiplatelet therapy with aspirin and clopidogrel reduces early recurrence of ischaemic stroke, with long-term use this type of therapy is no longer effective and the risk of bleeding increases. Given that cilostazol prevents stroke recurrence without increasing the

Delayed ischemic stroke after stent-assisted coil placement in cerebral aneurysm: characteristics and optimal duration of preventative dual antiplatelet therapy.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

OBJECTIVE To evaluate characteristics of delayed ischemic stroke after stent-assisted coil placement in cerebral aneurysms and to determine the optimal duration of dual antiplatelet therapy for its prevention. METHODS This retrospective study was approved by the institutional review board, and the

A comparison of three platelet function tests in ischemic stroke patients with antiplatelet therapy

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Predicting the effectiveness of antiplatelet drugs is critical to precision antiplatelet therapy. However, there is a lack of an acceptable method, although there are a variety of methods for detecting platelet function. In this study, we compared three major platelet function tests to assess their

Platelet function-guided modification in antiplatelet therapy after acute ischemic stroke is associated with clinical outcomes in patients with aspirin nonresponse.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

UNASSIGNED To investigate the association of clinical outcomes with platelet function-guided modification in antiplatelet therapy in patients with ischemic stroke. UNASSIGNED Among 812 patients, 223 patients had aspirin nonresponse, 204 patients was modified in antiplatelet therapy after platelet

Personalised antiplatelet therapy based on pharmacogenomics in acute ischaemic minor stroke and transient ischaemic attack: study protocol for a randomised controlled trial.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Antiplatelet therapy combining aspirin and clopidogrel is considered to be a key intervention for acute ischaemic minor stroke (AIMS) and transient ischaemic attack (TIA). However, the interindividual variability in response to clopidogrel resulting from the polymorphisms in

Stroke occurrence while on antiplatelet therapy may predict atrial fibrillation detected after stroke.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Stroke occurrence while on antiplatelet therapy, i.e., a breakthrough stroke, is often conveniently attributed to antiplatelet resistance. However, undetected paroxysmal atrial fibrillation (AF) may underlie breakthrough strokes. We hypothesized that a breakthrough stroke may be a

Prethodni
1
2
3
4
5
6
...
421
422
Sljedeći

Pridružite se našoj
facebook stranici

Herbal & Natural Medicine

Najkompletnija baza ljekovitog bilja potpomognuta naukom

Radi na 55 jezika
Biljni lijekovi potpomognuti naukom
Prepoznavanje biljaka po slici
Interaktivna GPS karta - označite bilje na lokaciji (uskoro)
Pročitajte naučne publikacije povezane sa vašom pretragom
Pretražite ljekovito bilje po učincima
Organizirajte svoja interesovanja i budite u toku sa istraživanjem vijesti, kliničkim ispitivanjima i patentima

Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Sve informacije temelje se na objavljenim naučnim istraživanjima